Clinical Trials Browser

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

Clinical Trials

PSMAddition

PSMACare

PSMA SRT

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

SatisfACtion

Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

PSMAfore

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

NeoPSMA

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

BiPASS

68Ga-PSMA PET/CT for Ra223 Assessment

Re-treatment 225Ac-J591 for mCRPC

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

HEATWAVE

PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer

GaPSMA

Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC

High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer

68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

PET/MRI to Stage Prostate Cancer Patients

Phase I Trial of 225Ac-J591 in Patients With mCRPC

Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

68Ga-PSMA PET/CT in Prostate Cancer

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer

68 Ga-PSMA for High Risk Prostate Cancer

PET/MRI in Patients With Suspected Prostate Cancer

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study

Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion

The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer